Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Crain's Chicago Business13h
Abbott Labs board OKs $7 billion stock buyback program
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
Abbott Laboratories: Strong Financial Performance and Growth Potential Justify Buy Rating
TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...
Benzinga.com20h
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott’s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20. Also Read: Abbott ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Jim Cramer Says That FDA, NIH, and CDC Comments On Abbott Laboratories (ABT) Could Potential Help The Stock Going Forward
We recently compiled a list of the Jim Cramer is Talking About These 14 Stocks Before Earnings. In this article, we are going ...
Abbott Laboratories' (NYSE:ABT) five-year earnings growth trails the respectable shareholder returns
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, ...